Form 4: BioAge Labs Director Receives Stock Option Grant

Director Rekha Hemrajani was granted 22,000 stock options in BioAge Labs, Inc. as part of an equity compensation award.

Summary

• Director Rekha Hemrajani acquired 22,000 stock options in BioAge Labs, Inc. (BIOA).
• The options have an exercise price of $15.48 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $15.48 exercise price.

Future Outlook

The options vest on the earlier of the next annual meeting of stockholders or the one-year anniversary of the grant date, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for publicly traded biotech firms.
• The 10-year expiration term is standard for executive and director stock option plans.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options at the next annual meeting or June 10, 2027.

Key Dates

Keywords

BioAge Labs, BIOA, Form 4, Director Compensation, Stock Options, Insider Transaction